AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Lung Therapeutics Announces Appointment of Cory M. Hogaboam, Ph.D., as Chief Scientific Officer

April 13, 2021 GMT
Cory M. Hogaboam, Ph.D, Chief Scientific Officer, Lung Therapeutics, Inc. (Photo: Business Wire)
Cory M. Hogaboam, Ph.D, Chief Scientific Officer, Lung Therapeutics, Inc. (Photo: Business Wire)

AUSTIN, Texas--(BUSINESS WIRE)--Apr 13, 2021--

Lung Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for orphan, pulmonary diseases and conditions, today announced the appointment of Cory M. Hogaboam, Ph.D., as Chief Scientific Officer. As CSO, Dr. Hogaboam will be responsible for guiding Lung Therapeutics’ scientific research and will serve as a key member of the company’s executive leadership team.

ADVERTISEMENT

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210413005530/en/

Cory M. Hogaboam, Ph.D, Chief Scientific Officer, Lung Therapeutics, Inc. (Photo: Business Wire)

Dr. Hogaboam’s distinguished career encompasses more than 20 years of scientific experience. He is a Professor of Medicine and Research Scientist in the Women’s Guild Lung Institute at Cedars Sinai Medical Center, and an Adjunct Professor of Pathology at the University of Michigan Medical School. Dr. Hogaboam is presently serving on the editorial board of the American Journal of Respiratory and Critical Care Medicine and the Journal of Clinical Investigation Insight. He has authored or co-authored 11 patents on therapeutic interventions for lung and liver. Dr. Hogaboam has received financial research support from the National Institutes of Health, American Lung Association, Canadian Institutes of Health Research, and several Industry sponsors. He is frequently invited to speak at national and international lung disease meetings and academic centers.

Brian Windsor, President & CEO, Lung Therapeutics, Inc. said, “With his outstanding record of scientific accomplishment, we are excited to have Dr. Hogaboam as our new CSO. He is a well-known thought leader in pulmonary fibrosis, and there is no better investigator to lead our research efforts.” Previously, Dr. Hogaboam served on Lung Therapeutics’ Medical Advisory Board. “Already familiar with our pioneering therapies, his scientific vision and experience will be invaluable as we advance our technology platform for addressing devastating fibrotic diseases and work to achieve our goal of bringing life-saving therapies to patients worldwide.”

ADVERTISEMENT

“I am excited to join Lung Therapeutics and work with such a dedicated and progressive leadership team. I look forward to providing scientific strategy guidance in developing the full therapeutic potential of the company’s groundbreaking technology,” said Dr. Hogaboam. “Based on the research and early clinical trials conducted, LTI drug candidates have the potential to help patients with serious and debilitating fibrotic diseases and conditions who currently lack effective treatment options.”

Lung Therapeutics is developing a proprietary pipeline of therapeutics with the potential to greatly improve outcomes over currently available treatments. The company’s lead drug candidate, LTI-01, is in clinical development for Loculated Pleural Effusion (LPE) and has successfully completed a clinical trial in LPE patients. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US. The company’s second drug candidate, LTI-03, is in clinical development for Idiopathic Pulmonary Fibrosis (IPF).

About Lung Therapeutics Inc.

Headquartered in Austin, Texas, Lung Therapeutics, Inc. is a clinical stage biopharmaceutical company formed to leverage leading research in orphan, pulmonary indications for which there are unmet medical needs. The company is developing a proprietary pipeline of novel therapeutics with the potential to greatly improve outcomes over currently available treatments. The company’s lead drug LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US. LTI-01 is currently in a Phase 2, randomized, placebo-controlled, double-blind, dose-ranging study evaluating LTI-01 in patients with infected, non-draining loculated pleural effusions. The company’s second product candidate, LTI-03, is in development for idiopathic pulmonary fibrosis. For more information, visit Lung Therapeutics, Inc.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210413005530/en/

CONTACT: Media Contact:

Sandra Oak, Nsight Public Relations, 321-591-1508,soak@nsightpr.com

Company Contact:

Charles T. Garner, Chief Financial Officer, Lung Therapeutics, Inc., 737- 802-1979,cgarner@lungtx.com

KEYWORD: TEXAS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Lung Therapeutics, Inc.

Copyright Business Wire 2021.

PUB: 04/13/2021 06:00 AM/DISC: 04/13/2021 06:01 AM

http://www.businesswire.com/news/home/20210413005530/en